AC Immune (ACIU) Expected to Release Quarterly Earnings on Tuesday

Posted by on Aug 2nd, 2026

AC Immune (NASDAQ:ACIU – Get Free Report) is projected to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $0.1214 per share and revenue of $34.0840 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

AC Immune (NASDAQ:ACIU – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $0.33 million. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Trading Down 7.6%

Shares of NASDAQ:ACIU opened at $2.19 on Friday. The stock’s 50-day simple moving average is $2.42 and its two-hundred day simple moving average is $2.81. The stock has a market capitalization of $222.88 million, a price-to-earnings ratio of -2.67 and a beta of 1.57. AC Immune has a 52-week low of $2.03 and a 52-week high of $4.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a report on Wednesday, July 1st. Finally, BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AC Immune presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Get Our Latest Stock Report on ACIU

Insider Activity at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of AC Immune stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the transaction, the chief executive officer directly owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. The trade was a 0.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On AC Immune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACIU. EFG International AG bought a new position in shares of AC Immune in the fourth quarter worth approximately $41,000. Marshall Wace LLP bought a new stake in shares of AC Immune during the 4th quarter valued at $586,000. Dimensional Fund Advisors LP raised its position in shares of AC Immune by 20.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after purchasing an additional 36,353 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after buying an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of AC Immune during the 3rd quarter valued at $63,000. Institutional investors own 51.36% of the company’s stock.

About AC Immune

(Get Free Report)

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.

Featured Stories

Earnings History for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.